17 terminated. 17 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Terminated 17 |
| Phase 1 | 4 | Terminated 4 |
| Phase 3 | 1 | Terminated 1 |
Follow niraparib: new trials by email Literature Review of niraparib trials Research Report on niraparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations Abiraterone Acetate/Niraparib, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 8 | 2024-03-05 | 2026-07-22 |
| Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation Bevacizumab, Niraparib - Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Terminated | University of Oklahoma | 9 | 2023-02-15 | 2026-06-03 |
| Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer Niraparib - Metastatic Pancreatic Cancer | Phase 2 | Terminated | Centre Leon Berard | 2 | 2022-10-28 | 2026-02-17 |
| PARP Inhibition for Gliomas (PI-4G or π4g) Niraparib - Recurrent Glioblastoma, Recurrent Astrocytoma | Phase 2 | Terminated | University of Oklahoma | 15 | 2022-06-09 | 2025-05-23 |
| A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C) Niraparib, Carboplatin, Paclitaxel - Ovarian Neoplasms | Phase 2 | Terminated | Tesaro, Inc. | 36 | 2022-04-14 | 2025-11-26 |
| Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors Niraparib - Solid Tumor, Breast Tumor | Phase 2 | Terminated | Tempus AI | 22 | 2022-03-15 | 2025-10-29 |
| Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors RP-3500 (camonsertib) - Advanced Solid Tumor, Adult | Phase 1 / Phase 2 | Terminated | Repare Therapeutics | 156 | 2021-07-21 | 2025-10-30 |
| Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab Dostarlimab, Niraparib - Urothelial Bladder Cancer, Gastric Adenocarcinoma | Phase 2 | Terminated | Gustave Roussy, Cancer Campus, Grand Paris | 51 | 2021-04-07 | 2025-12-01 |
| A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer External Beam Radiation, Niraparib, Vaginal high-dose rate brachytherapy - Endometrial Carcinoma, P53 Mutation | Phase 2 / Phase 3 | Terminated | University Health Network, Toronto | 11 | 2020-11-17 | 2025-08-12 |
| Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months AsiDNA, Niraparib, Olaparib - Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Gustave Roussy, Cancer Campus, Grand Paris | 13 | 2020-10-05 | 2024-12-05 |
| Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy - ATM Gene Mutation, BRCA1 Gene Mutation | Phase 2 | Terminated | University of California, Davis | 11 | 2020-02-25 | 2026-05-14 |
| Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer) Niraparib - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Terminated | Mario Negri Institute for Pharmacological Research | 83 | 2019-11-13 | 2025-01-17 |
| Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer Niraparib, Dostarlimab - Ovarian Neoplasms | Phase 2 | Terminated | Tesaro, Inc. | 41 | 2019-10-03 | 2022-09-10 |
| Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix Nirapaib - Metastatic Carcinoma of the Cervix | Phase 1 / Phase 2 | Terminated | Michelle S Ludwig | 4 | 2019-07-15 | 2024-09-03 |
| A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma Niraparib - Esophageal Cancer, Gastric Cancer | Phase 2 | Terminated | Shadia Jalal, MD | 14 | 2019-07-09 | 2024-06-04 |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) Atezolizumab, Enfortumab Vedotin, Niraparib - Urothelial Carcinoma, Bladder Cancer | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 272 | 2019-06-01 | 2026-08-03 |
| A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients Niraparib - Breast Cancer | Phase 2 | Terminated | The Netherlands Cancer Institute | 9 | 2018-05-15 | 2022-07-18 |
Ovarian Neoplasms (5) · Endometrial Neoplasms (3) · Breast Neoplasms (2) · Esophageal Neoplasms (2) · Head and Neck Neoplasms (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Adenocarcinoma (1) · Anemia (1) · Astrocytoma (1) · Biliary Tract Neoplasms (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Cystadenocarcinoma, Serous (1)
Gustave Roussy, Cancer Campus, Grand Paris (2) · Tesaro, Inc. (2) · University of Oklahoma (2) · Centre Leon Berard (1) · Hoffmann-La Roche (1) · Mario Negri Institute for Pharmacological Research (1) · Mayo Clinic (1) · Michelle S Ludwig (1) · Repare Therapeutics (1) · Shadia Jalal, MD (1) · Tempus AI (1) · The Netherlands Cancer Institute (1) · University Health Network, Toronto (1) · University of California, Davis (1)
United States (11) · France (4) · Canada (2) · Spain (2) · Germany (1) · Greece (1) · Italy (1) · Netherlands (1) · South Korea (1) · Taiwan (1) · United Kingdom (1)
Amit Oza, MD (1) · Daniel S. Childs, MD (1) · James Battiste, MD (1) · Lauren Dockery, MD (1) · Marc Dall'Era (1) · Michelle S Ludwig, MD, MPH, PhD (1) · Nicoletta Colombo, MD (1) · Shadia Jalal, MD (1) · Virginia Rhodes (1)
PMID 36710203, PMID 37185961, PMID 37651261, PMID 37890345, PMID 40705098, PMID 41950571
2023 (1), P30CA093373 (1)